Stockscreener 앱 받기
1.79%
Amgen Inc 주식(AMGN)의 최신 뉴스
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool
Amgen stock hits all-time high at 447.09 USD By Investing.com - Investing.com Canada
Amgen Foundation Tops $75 Million in Hands-On Biotechnology Education, Reaching 100,000 Students a Year - CSRwire
The Escalator: CSL, Insmed, Amgen and more - Medical Marketing and Media
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Amgen Inc. $AMGN Shares Sold by Foster Victor Wealth Advisors LLC - MarketBeat
35,730 Amgen Inc. $AMGN Shares Acquired by Crossmark Global Holdings Inc. - MarketBeat
Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price? - Yahoo Finance
Biotech ETF (BBH) Hits New 52-Week High - Zacks Investment Research
Amgen, AstraZeneca Detail Phase III Data For Tezspire’s Likely Third Indication - Scrip
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen Inc (AMGN) Shares Surge 3.3% -- What GF Score of 85 Tells Investors - GuruFocus
2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going) - The Motley Fool
AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 - PR Newswire
Amgen (AMGN) and AstraZeneca Report Positive Phase 3 Trial Resul - GuruFocus
From Discovery to Delivery: 5 Ways Amgen Is Putting Sustainability into Practice - www.marketscreener.com
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study - Benzinga
Amgen, AstraZeneca report phase 3 results for Tezspire in eosinophilic esophagitis - Seeking Alpha
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial - Reuters
TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS - Amgen
Amgen Inc. $AMGN Stock Bought by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat
Dona’s Story: Strengthening Her Bones After a Postmenopausal Osteoporosis Diagnosis - Amgen
10,773 Amgen Inc. $AMGN Shares Sold by Novem Group - MarketBeat
Greg Jennings LLC Buys New Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) options chain - Yahoo Finance Australia
Mattel appoints Amgen's Peter Griffith as CFO, succeeding Paul Ruh - Reuters
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
Amgen Has the Drugs and the Dividend. Now It Needs the Growth - Yahoo Finance
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Inc. $AMGN Stock Sold by First Bank & Trust - MarketBeat
2,560 Amgen Inc. $AMGN Shares Sold by Generali Investments Management Co LLC - MarketBeat
Beat the Market the Zacks Way: Valero Energy, Hagerty, Palantir in Focus - Zacks Investment Research
Amgen Inc. $AMGN Position Lifted by IFP Advisors Inc - MarketBeat
Amgen Inc. $AMGN Stock Sold by TD Waterhouse Canada Inc. - MarketBeat
Amgen Inc. $AMGN Stock: Frank Rimerman Advisors LLC Raises Holdings - MarketBeat
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
Here's Why Amgen (AMGN) is a Strong Momentum Stock - Zacks Investment Research
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? - The Motley Fool
Amgen (AMGN) Laps the Stock Market: Here's Why - Zacks Investment Research
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Stock Market News for Oct 8, 2026 - Zacks Investment Research
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
0.63%
자본화:
|
볼륨(24시간):